Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kymera Therapeutics, Inc. (KYMR)
USD110.40
-8.95 (-7.50%)
US NASDAQ Healthcare Biotechnology
Address
200 Arsenal Yards Boulevard 2472
Watertown, MA, US
Watertown, MA, US
CEO
Nello Mainolfi
Website
kymeratx.com
IPO
2020-08-21
CIK 1815442 ISIN US5015751044
Description
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
News Sentiment (7d)
Based on only 2 articles — low confidence
- Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader Globe News Wire
- Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD110.40
-8.95 (-7.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
764.4K
Beta
1.96
Float Shares
70.35M
Free Float %
86.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.65% | -3.64% | -1.76% | -0.56% | +31.51% | +7.38% | +159.71% | +194.71% | +73.92% | +151.20% | +151.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (26 ratings, all time)
Buy
Price Targets & DCF
Current price
110.40
Low
90.00
-18.5%
Consensus
118.06
+6.9%
Median
118.50
+7.3%
High
138.00
+25.0%
DCF (Unlevered)
0.11
-99.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
96% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 17 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
112.50
+1.9%
|
| Last Quarter | 4 |
114.00
+3.3%
|
| Last Year | 37 |
95.68
-13.3%
|
| All Time | 57 |
79.95
-27.6%
|
Quality scores
Altman Z-Score
30.98
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-16.7% Q1'26: +55.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-23.8% Q1'26: +13.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-738.5% Q1'26: -259.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-794.3% Q1'26: -201.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-38.3% Q1'26: -28.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+12.5% Q1'26: +21.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27× Q1'26: -0.30× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 17 EPS Ana. |
Dec 2027 17 Rev. Ana. 17 EPS Ana. |
Dec 2028 17 Rev. Ana. 14 EPS Ana. |
Dec 2029 14 Rev. Ana. 8 EPS Ana. |
Dec 2030 8 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.03M
est: 42.01M (-19.0%)
|
72.83M
est: 83.71M (-13.0%)
|
46.83M
est: 50.19M (-6.7%)
|
78.59M
est: 88.55M (-11.2%)
|
47.07M
est: 53.87M (-12.6%)
|
39.20M
est: 53.89M (-27.3%)
|
80.10M
10.57M – 131.43M
+48.6% YoY
|
39.50M
7.11M – 57.37M
-50.7% YoY
|
39.40M
39.11M – 39.70M
-0.2% YoY
|
48.26M
2.77M – 83.19M
+22.5% YoY
|
211.26M
12.13M – 364.18M
+337.8% YoY
|
| EBITDA |
-43.72M
est: -42.01M (-4.1%)
|
-97.65M
est: -76.73M (-27.3%)
|
-151.66M
est: -125.66M (-20.7%)
|
-143.20M
est: -88.55M (-61.7%)
|
-216.24M
est: -53.87M (-301.4%)
|
-303.06M
est: -53.89M (-462.4%)
|
-80.10M
-131.43M – -10.57M
-48.6% YoY
|
-39.50M
-57.37M – -7.11M
+50.7% YoY
|
-39.40M
-39.70M – -39.11M
+0.2% YoY
|
-48.26M
-83.19M – -2.77M
-22.5% YoY
|
-211.26M
-364.18M – -12.13M
-337.8% YoY
|
| EBIT |
-45.48M
est: -42.01M (-8.3%)
|
-100.04M
est: -79.00M (-26.6%)
|
-154.63M
est: -128.71M (-20.1%)
|
-146.77M
est: -88.55M (-65.7%)
|
-223.61M
est: -53.87M (-315.1%)
|
-311.37M
est: -53.89M (-477.8%)
|
-80.10M
-131.43M – -10.57M
-48.6% YoY
|
-39.50M
-57.37M – -7.11M
+50.7% YoY
|
-39.40M
-39.70M – -39.11M
+0.2% YoY
|
-48.26M
-83.19M – -2.77M
-22.5% YoY
|
-211.26M
-364.18M – -12.13M
-337.8% YoY
|
| Net Income |
-45.59M
est: -107.81M (+57.7%)
|
-100.22M
est: -78.75M (-27.3%)
|
-154.81M
est: -127.85M (-21.1%)
|
-146.96M
est: -157.85M (+6.9%)
|
-223.86M
est: -223.99M (+0.1%)
|
-311.40M
est: -286.03M (-8.9%)
|
-334.35M
-364.12M – -234.46M
-16.9% YoY
|
-424.68M
-433.52M – -278.32M
-27.0% YoY
|
-455.61M
-492.00M – -300.66M
-7.3% YoY
|
-406.00M
-788.07M – 91.48M
+10.9% YoY
|
-323.86M
-628.63M – 72.98M
+20.2% YoY
|
| SGA |
18.23M
est: 33.78M (-46.0%)
|
36.35M
est: 28.72M (+26.5%)
|
43.83M
est: 40.49M (+8.3%)
|
55.04M
est: 92.53M (-40.5%)
|
63.53M
est: 56.30M (+12.9%)
|
68.20M
est: 56.32M (+21.1%)
|
83.70M
11.04M – 137.34M
+48.6% YoY
|
41.27M
7.43M – 59.95M
-50.7% YoY
|
41.18M
40.87M – 41.48M
-0.2% YoY
|
50.43M
2.90M – 86.93M
+22.5% YoY
|
220.76M
12.68M – 380.57M
+337.8% YoY
|
| EPS |
-0.99
est: -1.44 (+31.1%)
|
-2.09
est: -1.86 (-12.1%)
|
-2.87
est: -2.90 (+1.0%)
|
-2.52
est: -2.42 (-4.1%)
|
-2.98
est: -2.82 (-5.6%)
|
-3.69
est: -3.45 (-7.0%)
|
-3.51
-4.31 – -2.78
-1.9% YoY
|
-4.32
-5.14 – -3.30
-22.8% YoY
|
-4.70
-5.83 – -3.56
-8.9% YoY
|
-4.81
-9.34 – 1.08
-2.4% YoY
|
-3.84
-7.45 – 0.86
+20.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-252.53M
OE per share TTM
-2.91
Owner's Yield
-3.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
115.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
51
Total invested
88.16M
Insider transactions (90d)
3
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Venture Associates X, L.P. | 7.95M | 17.90% | — | 7.95M | — | 7.95M | PN | Delaware | 2021-02-16 | ↗ |
| 2 | Venture Fund X, L.P. | 7.95M | 17.90% | — | 7.95M | — | 7.95M | PN | Delaware | 2021-02-16 | ↗ |
| 3 | Baker Bros. Advisors (GP) LLC | 6.00M | 9.80% | 6.00M | — | 6.00M | — | HC, OO | Delaware | 2024-04-01 | ↗ |
| 4 | Baker Bros. Advisors LP | 6.00M | 9.80% | 6.00M | — | 6.00M | — | IA, PN | Delaware | 2024-04-01 | ↗ |
| 5 | Felix J. Baker | 6.00M | 9.80% | 6.00M | — | 6.00M | — | HC, IN | United States | 2024-04-01 | ↗ |
| 6 | Julian C. Baker | 6.00M | 9.80% | 6.00M | — | 6.00M | — | HC, IN | United States | 2024-04-01 | ↗ |
| 7 | Atlas Venture Associates X, L.P. | 5.76M | 11.20% | — | 5.76M | — | 5.76M | PN | Delaware | 2022-02-11 | ↗ |
| 8 | Atlas Venture Fund X, L.P. | 5.76M | 11.20% | — | 5.76M | — | 5.76M | PN | Delaware | 2022-02-11 | ↗ |
| 9 | 52-0556948 | 5.22M | 10.10% | 1.29M | — | 5.22M | — | IA | Maryland | 2022-07-11 | ↗ |
| 10 | Abigail P. Johnson | 5.11M | 7.93% | — | — | 5.11M | — | IN | Delaware | 2024-11-12 | ↗ |
| 11 | FMR LLC | 5.11M | 7.93% | 5.11M | — | 5.11M | — | HC | Delaware | 2024-11-12 | ↗ |
| 12 | Avoro Capital Advisors LLC | 3.85M | 7.00% | 3.85M | — | 3.85M | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 13 | Behzad Aghazadeh | 3.85M | 7.00% | 3.85M | — | 3.85M | — | IN | United States | 2023-02-14 | ↗ |
| 14 | (1) BlackRock, Inc. | 3.40M | 6.60% | 3.37M | — | 3.40M | — | HC | Delaware | 2022-02-04 | ↗ |
| 15 | Vertex Pharmaceuticals Incorporated | 3.15M | 7.10% | 3.15M | — | 3.15M | 11.00 | CO | — | 2020-09-03 | ↗ |
| 16 | The Vanguard Group - 23-1945930 | 2.96M | 5.75% | — | 64.4K | — | 88.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 17 | STATE STREET CORPORATION | 2.85M | 5.19% | — | 2.78M | — | 2.85M | HC | — | 2023-02-08 | ↗ |
| 18 | Wellington Group Holdings LLP | 2.69M | 5.24% | — | 2.27M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 19 | Wellington Investment Advisors Holdings LLP | 2.69M | 5.24% | — | 2.27M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 20 | Wellington Management Group LLP | 2.69M | 5.24% | — | 2.27M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 21 | BVF INC. | 2.63M | 5.90% | — | — | — | 2.63M | CO | — | 2020-08-25 | ↗ |
| 22 | BVF PARTNERS L.P. | 2.63M | 5.90% | — | — | — | 2.63M | IA, PN | — | 2020-08-25 | ↗ |
| 23 | MARK N. LAMPERT | 2.63M | 5.90% | — | — | — | 2.63M | IN | — | 2020-08-25 | ↗ |
| 24 | Jeremy C. Green | 2.59M | 5.00% | — | 2.59M | — | 2.59M | HC, IN | United Kingdom | 2022-02-14 | ↗ |
| 25 | Redmile Group, LLC | 2.59M | 5.00% | — | 2.59M | — | 2.59M | IA, OO | Delaware | 2022-02-14 | ↗ |
| 26 | BVF GP HOLDINGS LLC | 2.38M | 5.30% | — | — | — | 2.38M | OO | — | 2020-08-25 | ↗ |
| 27 | BIOTECHNOLOGY VALUE FUND, L.P. | 1.36M | 3.10% | — | — | — | 1.36M | PN | — | 2020-08-25 | ↗ |
| 28 | BVF I GP LLC | 1.36M | 3.10% | — | — | — | 1.36M | OO | — | 2020-08-25 | ↗ |
| 29 | Venture Associates Opportunity I, L.P. | 1.11M | 2.50% | — | 1.11M | — | 1.11M | PN | Delaware | 2021-02-16 | ↗ |
| 30 | Venture Opportunity Fund I, L.P. | 1.11M | 2.50% | — | 1.11M | — | 1.11M | PN | Delaware | 2021-02-16 | ↗ |
| 31 | Atlas Venture Associates Opportunity I, L.P. | 1.11M | 2.20% | — | 1.11M | — | 1.11M | PN | Delaware | 2022-02-11 | ↗ |
| 32 | Atlas Venture Opportunity Fund I, L.P. | 1.11M | 2.20% | — | 1.11M | — | 1.11M | PN | Delaware | 2022-02-11 | ↗ |
| 33 | BIOTECHNOLOGY VALUE FUND II, L.P. | 1.02M | 2.30% | — | — | — | 1.02M | PN | — | 2020-08-25 | ↗ |
| 34 | BVF II GP LLC | 1.02M | 2.30% | — | — | — | 1.02M | OO | — | 2020-08-25 | ↗ |
| 35 | BIOTECHNOLOGY VALUE TRADING FUND OS, L.P. | 181.1K | 1.00% | — | — | — | 181.1K | PN | — | 2020-08-25 | ↗ |
| 36 | BVF PARTNERS OS LTD. | 181.1K | 1.00% | — | — | — | 181.1K | CO | — | 2020-08-25 | ↗ |
| 37 | Gorjan Hrustanovic | 2.2K | 1.00% | — | — | 2.2K | — | IN | — | 2020-08-25 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
51
-211 vs prev Q
New positions
12
Closed positions
215
Increased
30
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 8.93M +3.0M (+51.9%) | 694.73M +361.9M (+108.8%) | 10.23% +3.493 pp | 0.04% +0.018 pp | USD53.10 +46.5% | 22 qtrs — |
| 2 | BAKER BROS. ADVISORS LP | 8.66M +2.0M (+30.2%) | 673.62M +297.1M (+78.9%) | 9.92% +2.298 pp | 3.94% +1.224 pp | USD40.89 +90.3% | 22 qtrs — |
| 3 | AVORO CAPITAL ADVISORS LLC | 7.47M +1.1M (+17.7%) | 581.61M +222.2M (+61.8%) | 8.56% +1.288 pp | 5.59% +0.946 pp | USD39.16 +98.7% | 18 qtrs — |
| 4 | VANGUARD GROUP INC | 6.27M +845.9K (+15.6%) | 487.69M +180.8M (+58.9%) | 7.18% +0.969 pp | 0.01% +0.003 pp | USD44.26 +75.8% | 22 qtrs — |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 6.16M +1.1M (+20.8%) | 479.26M +190.7M (+66.1%) | 7.06% +1.216 pp | 0.05% +0.021 pp | USD45.84 +69.7% | 22 qtrs — |
| 6 | BVF INC/IL | 5.50M +— (+0.0%) | 428.17M +116.7M (+37.5%) | 6.30% +0.000 pp | 14.41% +1.788 pp | USD33.52 +132.1% | 22 qtrs — |
| 7 | BLACKROCK, INC. | 5.00M +638.6K (+14.6%) | 389.37M +142.3M (+57.6%) | 5.73% +0.732 pp | 0.01% +0.002 pp | USD51.43 +51.3% | 6 qtrs — |
| 8 | ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 4.66M -236.6K (-4.8%) | 362.58M +85.4M (+30.8%) | 5.34% -0.271 pp | 41.91% +5.087 pp | USD63.49 +22.6% | 17 qtrs — |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 4.41M -782.8K (-15.1%) | 343.37M +49.3M (+16.8%) | 5.05% -0.897 pp | 0.06% +0.009 pp | USD34.81 +123.5% | 22 qtrs — |
| 10 | SIREN, L.L.C. | 3.29M -141.3K (-4.1%) | 255.75M +61.7M (+31.8%) | 3.77% -0.162 pp | 7.63% +0.038 pp | USD45.55 +70.8% | 6 qtrs — |
| 11 | STATE STREET CORP | 2.21M +190.4K (+9.4%) | 171.95M +57.6M (+50.4%) | 2.53% +0.218 pp | 0.01% +0.002 pp | USD43.93 +77.1% | 21 qtrs — |
| 12 | CAPITAL RESEARCH GLOBAL INVESTORS | 1.56M +298.6K (+23.7%) | 121.45M +50.0M (+70.0%) | 1.79% +0.342 pp | 0.02% +0.009 pp | USD46.37 +67.8% | 4 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.42M +140.6K (+11.0%) | 110.31M +38.0M (+52.6%) | 1.62% +0.161 pp | 0.01% +0.002 pp | USD47.75 +63.0% | 22 qtrs — |
| 14 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.07M +130.1K (+13.9%) | 83.20M +30.0M (+56.5%) | 1.22% +0.149 pp | 0.57% +0.184 pp | USD48.51 +60.4% | 7 qtrs — |
| 15 | ALLIANCEBERNSTEIN L.P. | 952.1K +903.3K (+1,852.2%) | 74.08M +71.3M (+2,583.7%) | 1.09% +1.035 pp | 0.02% +0.023 pp | USD76.07 +2.3% | 21 qtrs — |
| 16 | UBS ASSET MANAGEMENT AMERICAS INC | 912.5K +48.7K (+5.6%) | 71.00M +22.1M (+45.2%) | 1.05% +0.056 pp | 0.02% +0.004 pp | USD34.90 +123.0% | 19 qtrs — |
| 17 | MERCK & CO., INC. | 772.2K +— (+0.0%) | 60.08M +16.4M (+37.5%) | 0.88% +0.000 pp | 21.75% +2.581 pp | USD40.23 +93.4% | 5 qtrs — |
| 18 | FEDERATED HERMES, INC. | 763.9K +205.2K (+36.7%) | 59.44M +27.8M (+88.0%) | 0.88% +0.235 pp | 0.10% +0.044 pp | USD62.30 +24.9% | 2 qtrs — |
| 19 | HOLOCENE ADVISORS, LP | 761.2K -79.1K (-9.4%) | 59.23M +11.7M (+24.5%) | 0.87% -0.091 pp | 0.12% +0.016 pp | USD56.60 +37.5% | 2 qtrs — |
| 20 | COMMODORE CAPITAL LP | 750.0K +— (+0.0%) | 58.36M +15.9M (+37.5%) | 0.86% +0.000 pp | 3.88% +1.812 pp | USD43.64 +78.3% | 3 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 740.3K +28.9K (+4.1%) | 57.60M +17.3M (+43.1%) | 0.85% +0.033 pp | 0.01% +0.002 pp | USD49.45 +57.4% | 22 qtrs — |
| 22 | UBS GROUP AG | 737.0K +88.3K (+13.6%) | 57.35M +20.6M (+56.2%) | 0.84% +0.101 pp | 0.01% +0.004 pp | USD41.41 +87.9% | 22 qtrs — |
| 23 | FRONTIER CAPITAL MANAGEMENT CO LLC | 636.0K +117.9K (+22.8%) | 49.48M +20.2M (+68.8%) | 0.73% +0.135 pp | 0.53% +0.262 pp | USD51.28 +51.7% | 6 qtrs — |
| 24 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 629.7K +18.5K (+3.0%) | 49.00M +14.4M (+41.6%) | 0.72% +0.021 pp | 0.03% +0.010 pp | USD55.36 +40.6% | 3 qtrs — |
| 25 | EVENTIDE ASSET MANAGEMENT, LLC | 626.4K -18.2K (-2.8%) | 48.74M +12.3M (+33.6%) | 0.72% -0.021 pp | 0.76% +0.162 pp | USD35.83 +117.2% | 8 qtrs — |
| 26 | DIMENSIONAL FUND ADVISORS LP | 624.0K -107.4K (-14.7%) | 48.56M +7.1M (+17.3%) | 0.71% -0.123 pp | 0.01% +0.001 pp | USD41.55 +87.3% | 17 qtrs — |
| 27 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 561.2K -11.1K (-1.9%) | 43.66M +11.3M (+34.8%) | 0.64% -0.013 pp | 0.56% +0.063 pp | USD40.54 +91.9% | 5 qtrs — |
| 28 | OCTAGON CAPITAL ADVISORS LP | 535.0K +175.0K (+48.6%) | 41.63M +21.3M (+104.3%) | 0.61% +0.201 pp | 5.05% +1.966 pp | USD57.09 +36.3% | 3 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 497.0K +57.2K (+13.0%) | 38.67M +13.8M (+55.4%) | 0.57% +0.066 pp | 0.01% +0.002 pp | USD51.61 +50.8% | 21 qtrs — |
| 30 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 496.9K +46.5K (+10.3%) | 38.66M +13.2M (+51.7%) | 0.57% +0.053 pp | 1.98% +0.493 pp | USD34.26 +127.1% | 22 qtrs — |
| 31 | JENNISON ASSOCIATES LLC | 496.7K -531.1K (-51.7%) | 38.65M -19.5M (-33.6%) | 0.57% -0.608 pp | 0.02% -0.011 pp | USD45.87 +69.6% | 8 qtrs — |
| 32 | PICTET ASSET MANAGEMENT HOLDING SA | 483.2K +136.4K (+39.3%) | 37.79M +18.0M (+91.0%) | 0.55% +0.156 pp | 0.04% +0.018 pp | USD62.44 +24.6% | 3 qtrs — |
| 33 | NORTHERN TRUST CORP | 467.0K +29.9K (+6.8%) | 36.34M +11.6M (+46.9%) | 0.54% +0.034 pp | 0.00% +0.002 pp | USD51.15 +52.1% | 21 qtrs — |
| 34 | BRAIDWELL LP | 454.3K +177.6K (+64.2%) | 35.35M +19.7M (+125.7%) | 0.52% +0.203 pp | 1.13% +0.666 pp | USD64.89 +19.9% | 2 qtrs — |
| 35 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 430.0K +192.0K (+80.7%) | 33.46M +20.0M (+148.4%) | 0.49% +0.220 pp | 0.05% +0.029 pp | USD58.90 +32.1% | 3 qtrs — |
| 36 | TWO SIGMA ADVISERS, LP | 373.8K +1.4K (+0.4%) | 29.09M +8.0M (+38.0%) | 0.43% +0.002 pp | 0.06% +0.014 pp | USD41.11 +89.3% | 17 qtrs — |
| 37 | ALYESKA INVESTMENT GROUP, L.P. | 371.9K -243.2K (-39.5%) | 28.94M -5.9M (-16.9%) | 0.43% -0.279 pp | 0.08% -0.024 pp | USD55.55 +40.1% | 3 qtrs — |
| 38 | FRANKLIN RESOURCES INC | 354.6K +322.9K (+1,019.9%) | 27.59M +25.8M (+1,439.5%) | 0.41% +0.370 pp | 0.01% +0.006 pp | USD74.13 +5.0% | 7 qtrs — |
| 39 | BANK OF AMERICA CORP /DE/ | 339.0K +152.7K (+82.0%) | 26.38M +15.8M (+150.2%) | 0.39% +0.157 pp | 0.00% +0.001 pp | USD58.50 +33.0% | 22 qtrs — |
| 40 | BOXER CAPITAL MANAGEMENT, LLC | 329.1K +10.0K (+3.1%) | 25.61M +7.5M (+41.8%) | 0.38% -0.020 pp | 5.60% -0.152 pp | USD42.19 +84.4% | 5 qtrs — |
| 41 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 289.4K -145.6K (-33.5%) | 22.52M -2.1M (-8.5%) | 0.33% -0.167 pp | 0.01% 0.000 pp | USD30.59 +154.4% | 12 qtrs — |
| 42 | NEXTECH INVEST, LTD. | 278.9K -62.0K (-18.2%) | 21.70M +2.4M (+12.5%) | 0.32% -0.071 pp | 2.10% -0.839 pp | USD43.64 +78.3% | 3 qtrs — |
| 43 | MORGAN STANLEY | 274.0K -103.8K (-27.5%) | 21.32M -62.1K (-0.3%) | 0.31% -0.119 pp | 0.00% +0.000 pp | USD42.42 +83.4% | 22 qtrs — |
| 44 | TWO SIGMA INVESTMENTS, LP | 265.5K -164.4K (-38.2%) | 20.66M -3.7M (-15.1%) | 0.30% -0.188 pp | 0.03% -0.007 pp | USD46.93 +65.8% | 17 qtrs — |
| 45 | RTW INVESTMENTS, LP | 240.0K +240.0K (+100.0%) | 18.67M +18.7M (+100.0%) | 0.27% +0.275 pp | 0.19% +0.187 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 46 | GILDER GAGNON HOWE & CO LLC | 239.9K -6.8K (-2.8%) | 18.67M +4.7M (+33.7%) | 0.27% -0.008 pp | 0.20% +0.055 pp | USD43.41 +79.2% | 19 qtrs — |
| 47 | DEER MANAGEMENT CO. LLC | 230.8K -95.1K (-29.2%) | 17.96M -486.3K (-2.6%) | 0.26% -0.109 pp | 1.75% +0.095 pp | USD63.49 +22.6% | 17 qtrs — |
| 48 | TD ASSET MANAGEMENT INC | 221.2K +11.9K (+5.7%) | 17.21M +5.4M (+45.3%) | 0.25% +0.014 pp | 0.01% +0.004 pp | USD36.02 +116.0% | 22 qtrs — |
| 49 | FIRST TURN MANAGEMENT, LLC | 206.4K -71.3K (-25.7%) | 16.06M +344.2K (+2.2%) | 0.24% -0.082 pp | 1.84% -0.525 pp | USD56.60 +37.5% | 2 qtrs — |
| 50 | WOODLINE PARTNERS LP | 203.6K -44.4K (-17.9%) | 15.84M +1.8M (+12.9%) | 0.23% -0.051 pp | 0.06% -0.005 pp | USD35.63 +118.4% | 15 qtrs — |
| 51 | CANDRIAM S.C.A. | 201.7K +10.0K (+5.2%) | 15.69M +4.8M (+44.7%) | 0.23% +0.012 pp | 0.08% +0.021 pp | USD47.75 +63.0% | 3 qtrs — |
| 52 | POLAR CAPITAL HOLDINGS PLC | 200.9K -196.1K (-49.4%) | 15.64M -6.8M (-30.4%) | 0.23% -0.225 pp | 0.06% -0.048 pp | USD48.44 +60.6% | 3 qtrs — |
| 53 | BANK OF NEW YORK MELLON CORP | 192.7K +40.3K (+26.4%) | 15.00M +6.4M (+73.8%) | 0.22% +0.046 pp | 0.00% +0.001 pp | USD50.13 +55.2% | 21 qtrs — |
| 54 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 189.9K +189.9K (+100.0%) | 14.78M +14.8M (+100.0%) | 0.22% +0.218 pp | 0.22% +0.223 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 55 | POINT72 ASSET MANAGEMENT, L.P. | 173.1K -753.0 (-0.4%) | 13.47M +3.6M (+36.9%) | 0.20% -0.001 pp | 0.02% -0.001 pp | USD43.64 +78.3% | 3 qtrs — |
| 56 | CITADEL ADVISORS LLC | 159.9K +118.0K (+282.2%) | 12.44M +10.1M (+425.5%) | 0.18% +0.135 pp | 0.00% +0.002 pp | USD68.85 +13.0% | 20 qtrs — |
| 57 | SQUAREPOINT OPS LLC | 159.4K -191.8K (-54.6%) | 12.40M -7.5M (-37.6%) | 0.18% -0.220 pp | 0.01% -0.007 pp | USD54.16 +43.7% | 10 qtrs — |
| 58 | FORESITE CAPITAL MANAGEMENT VI LLC | 146.3K +— (+0.0%) | 11.39M +3.1M (+37.5%) | 0.17% +0.000 pp | 3.44% +0.242 pp | USD40.23 +93.4% | 5 qtrs — |
| 59 | BARCLAYS PLC | 140.5K +48.8K (+53.1%) | 10.93M +6.6M (+151.7%) | 0.16% +0.047 pp | 0.00% +0.002 pp | USD51.75 +50.4% | 16 qtrs — |
| 60 | PATIENT SQUARE CAPITAL LP | 139.0K +46.4K (+50.1%) | 10.82M +5.6M (+106.4%) | 0.16% +0.053 pp | 2.32% +0.914 pp | USD44.21 +76.0% | 4 qtrs — |
| 61 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 135.9K +9.4K (+7.4%) | 10.61M +3.4M (+48.2%) | 0.16% +0.011 pp | 0.01% +0.003 pp | USD40.33 +92.9% | 21 qtrs — |
| 62 | EAGLE HEALTH INVESTMENTS LP | 136.3K +136.3K (+100.0%) | 10.61M +10.6M (+100.0%) | 0.16% +0.156 pp | 2.33% +2.331 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 63 | JPMORGAN CHASE & CO | 131.4K -61.3K (-31.8%) | 10.22M -686.2K (-6.3%) | 0.15% -0.089 pp | 0.00% +0.000 pp | USD42.38 +83.6% | 21 qtrs — |
| 64 | LOGOS GLOBAL MANAGEMENT LP | 130.0K -120.0K (-48.0%) | 10.12M -4.0M (-28.5%) | 0.15% -0.138 pp | 0.61% -0.657 pp | USD56.60 +37.5% | 2 qtrs — |
| 65 | NUVEEN, LLC | 125.1K +18.3K (+17.2%) | 9.73M +3.7M (+61.1%) | 0.14% +0.021 pp | 0.00% +0.001 pp | USD36.23 +114.8% | 4 qtrs — |
| 66 | LMR PARTNERS LLP | 121.4K +121.4K (+100.0%) | 9.45M +9.4M (+100.0%) | 0.14% +0.139 pp | 0.02% +0.018 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 67 | INVESCO LTD. | 116.7K +36.9K (+46.3%) | 9.08M +4.6M (+101.1%) | 0.13% +0.042 pp | 0.00% +0.001 pp | USD56.88 +36.8% | 19 qtrs — |
| 68 | WCM INVESTMENT MANAGEMENT, LLC | 105.2K +105.2K (+100.0%) | 8.22M +8.2M (+100.0%) | 0.12% +0.121 pp | 0.02% +0.017 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 69 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 105.6K -2.1K (-2.0%) | 8.21M +2.1M (+34.7%) | 0.12% -0.003 pp | 0.01% +0.003 pp | USD40.98 +89.9% | 5 qtrs — |
| 70 | MONASHEE INVESTMENT MANAGEMENT LLC | 100.0K +100.0K (+100.0%) | 7.78M +7.8M (+100.0%) | 0.11% +0.115 pp | 4.38% +4.385 pp | USD77.81 +0.0% | 3 qtrs — |
| 71 | ENSIGN PEAK ADVISORS, INC | 95.0K +3.2K (+3.4%) | 7.40M +2.2M (+42.2%) | 0.11% +0.004 pp | 0.01% +0.005 pp | USD44.77 +73.8% | 3 qtrs — |
| 72 | SWISS NATIONAL BANK | 94.2K +12.6K (+15.4%) | 7.33M +2.7M (+58.7%) | 0.11% +0.014 pp | 0.00% +0.002 pp | USD48.67 +59.9% | 21 qtrs — |
| 73 | ARMISTICE CAPITAL, LLC | 81.2K +81.2K (+100.0%) | 6.32M +6.3M (+100.0%) | 0.09% +0.093 pp | 0.08% +0.075 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 74 | DEUTSCHE BANK AG\ | 79.8K +7.1K (+9.8%) | 6.21M +2.1M (+50.9%) | 0.09% +0.008 pp | 0.00% +0.001 pp | USD48.56 +60.2% | 21 qtrs — |
| 75 | BURKEHILL GLOBAL MANAGEMENT, LP | 75.0K +— (+0.0%) | 5.84M +1.6M (+37.5%) | 0.09% +0.000 pp | 0.38% +0.143 pp | USD43.64 +78.3% | 3 qtrs — |
| 76 | YIHENG CAPITAL MANAGEMENT, L.P. | 73.4K -49.2K (-40.1%) | 5.71M -1.2M (-17.7%) | 0.08% -0.056 pp | 1.16% +0.133 pp | USD27.37 +184.3% | 4 qtrs — |
| 77 | RHUMBLINE ADVISERS | 72.3K -1.9K (-2.5%) | 5.63M +1.4M (+34.0%) | 0.08% -0.002 pp | 0.00% +0.001 pp | USD38.59 +101.6% | 21 qtrs — |
| 78 | PERCEPTIVE ADVISORS LLC | 69.9K -99.9K (-58.8%) | 5.44M -4.2M (-43.4%) | 0.08% -0.114 pp | 0.10% -0.181 pp | USD43.64 +78.3% | 3 qtrs — |
| 79 | VICTORY CAPITAL MANAGEMENT INC | 67.1K +35.8K (+114.4%) | 5.22M +3.4M (+194.8%) | 0.08% +0.041 pp | 0.00% +0.002 pp | USD61.49 +26.5% | 8 qtrs — |
| 80 | WELLS FARGO & COMPANY/MN | 66.5K +34.4K (+107.4%) | 5.17M +3.4M (+185.1%) | 0.08% +0.039 pp | 0.00% +0.001 pp | USD59.39 +31.0% | 21 qtrs — |
| 81 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 64.8K +64.4K (+15,622.1%) | 5.04M +5.0M (+21,813.0%) | 0.07% +0.074 pp | 0.01% +0.006 pp | USD77.61 +0.3% | 3 qtrs — |
| 82 | ALPS ADVISORS INC | 64.7K +64.7K (+100.0%) | 5.04M +5.0M (+100.0%) | 0.07% +0.074 pp | 0.03% +0.029 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 83 | FIRST TRUST ADVISORS LP | 58.9K -16.0K (-21.4%) | 4.58M +343.4K (+8.1%) | 0.07% -0.018 pp | 0.00% +0.000 pp | USD56.60 +37.5% | 8 qtrs — |
| 84 | RAFFERTY ASSET MANAGEMENT, LLC | 58.7K -9.6K (-14.1%) | 4.56M +698.3K (+18.1%) | 0.07% -0.011 pp | 0.02% +0.003 pp | USD45.65 +70.4% | 20 qtrs — |
| 85 | NEUBERGER BERMAN GROUP LLC | 58.5K +58.5K (+100.0%) | 4.55M +4.6M (+100.0%) | 0.07% +0.067 pp | 0.00% +0.003 pp | USD77.81 +0.0% | 1 qtrs NEW |
| 86 | EAM INVESTORS, LLC | 56.5K -1.1K (-2.0%) | 4.39M +1.2M (+37.0%) | 0.06% -0.001 pp | 0.49% +0.122 pp | USD56.60 +37.5% | 2 qtrs — |
| 87 | NICHOLAS INVESTMENT PARTNERS, LP | 55.8K +3.2K (+6.0%) | 4.34M +1.4M (+45.7%) | 0.06% +0.004 pp | 0.32% +0.089 pp | USD57.80 +34.6% | 2 qtrs — |
| 88 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 54.9K +16.6K (+43.3%) | 4.27M +2.1M (+97.1%) | 0.06% +0.019 pp | 0.00% +0.000 pp | USD59.31 +31.2% | 6 qtrs — |
| 89 | VERITION FUND MANAGEMENT LLC | 54.3K +22.8K (+72.6%) | 4.23M +2.4M (+137.3%) | 0.06% +0.026 pp | 0.02% +0.009 pp | USD61.07 +27.4% | 7 qtrs — |
| 90 | SCHRODER INVESTMENT MANAGEMENT GROUP | 52.7K -9.0K (-14.6%) | 4.11M +508.7K (+14.1%) | 0.06% -0.010 pp | 0.00% +0.000 pp | USD26.82 +190.1% | 11 qtrs — |
| 91 | COMERICA BANK | 49.8K -1.6K (-3.1%) | 3.88M +965.3K (+33.2%) | 0.06% -0.002 pp | 0.02% +0.005 pp | USD44.68 +74.1% | 10 qtrs — |
| 92 | RUSSELL INVESTMENTS GROUP, LTD. | 46.0K +27.0K (+142.1%) | 3.58M +2.5M (+232.8%) | 0.05% +0.031 pp | 0.00% +0.003 pp | USD56.18 +38.5% | 15 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 45.7K +5.0K (+12.4%) | 3.56M +1.3M (+54.5%) | 0.05% +0.006 pp | 0.00% +0.001 pp | USD50.15 +55.2% | 21 qtrs — |
| 94 | LEGAL & GENERAL GROUP PLC | 43.4K -69.0 (-0.2%) | 3.38M +917.2K (+37.3%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD40.87 +90.4% | 21 qtrs — |
| 95 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 40.8K +13.9K (+51.5%) | 3.17M +1.6M (+107.4%) | 0.05% +0.016 pp | 0.00% +0.002 pp | USD47.97 +62.2% | 7 qtrs — |
| 96 | DARK FOREST CAPITAL MANAGEMENT LP | 39.2K +8.2K (+26.3%) | 3.05M +1.3M (+73.6%) | 0.04% +0.009 pp | 0.14% +0.087 pp | USD43.66 +78.2% | 6 qtrs — |
| 97 | MOODY ALDRICH PARTNERS LLC | 38.5K +9.6K (+33.3%) | 3.00M +1.4M (+83.2%) | 0.04% +0.011 pp | 0.56% +0.249 pp | USD52.17 +49.1% | 3 qtrs — |
| 98 | MARSHALL WACE, LLP | 38.0K -321.1K (-89.4%) | 2.96M -17.4M (-85.4%) | 0.04% -0.368 pp | 0.00% -0.018 pp | USD37.96 +105.0% | 11 qtrs — |
| 99 | Y-INTERCEPT (HONG KONG) LTD | 36.4K +36.4K (+100.0%) | 2.83M +2.8M (+100.0%) | 0.04% +0.042 pp | 0.06% +0.063 pp | USD77.81 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.37
Bearish
Ratio by volume
0.46
Bearish
Buys
13
Sells
35
Shares acquired
70.9K
Shares disposed
154.0K
Cash buys
—
Cash sales
22.00
Net activity
-83,196
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 2.08 | 62.4K | 696,195 | D | ↗ |
| 2026-04-22 | Chadwick Jeremy G | Officer | M-Exempt | D | Stock Option (Right to Buy) | 100 | 30.17 | 3.0K | 45,434 | D | ↗ |
| 2026-04-22 | Booth Bruce | Director | S-Sale | D | Common Stock | 5,900 | 89.96 | 530.8K | 0 | D | ↗ |
| 2026-04-15 | Chadwick Jeremy G | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,300 | 43.50 | 56.6K | 58,463 | D | ↗ |
| 2026-04-15 | Booth Bruce | Director | S-Sale | D | Common Stock | 2,750 | 90.10 | 247.8K | 3,899,917 | I | ↗ |
| 2026-04-14 | Goodman Noah | Officer | S-Sale | D | Common Stock | 1,347 | 90.00 | 121.2K | 50,195 | D | ↗ |
| 2026-04-14 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 5,251 | 90.00 | 472.6K | 61,202 | D | ↗ |
| 2026-04-14 | Booth Bruce | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,159 | 14.18 | 59.0K | 7,841 | D | ↗ |
| 2026-04-10 | Goodman Noah | Officer | S-Sale | D | Common Stock | 2,000 | 87.35 | 174.7K | 51,542 | D | ↗ |
| 2026-04-09 | Goodman Noah | Officer | S-Sale | D | Common Stock | 2,670 | 87.11 | 232.6K | 56,042 | D | ↗ |
| 2026-04-01 | Ridloff Elena | Director | S-Sale | D | Common Stock | 1,200 | 86.05 | 103.3K | 0 | D | ↗ |
| 2026-04-01 | Chadwick Jeremy G | Officer | M-Exempt | A | Common Stock | 14,640 | 29.64 | 433.9K | 75,842 | D | ↗ |
| 2026-03-31 | Ridloff Elena | Director | M-Exempt | D | Stock Option (Right to Buy) | 7,400 | 14.18 | 104.9K | 4,600 | D | ↗ |
| 2026-03-31 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 7,600 | 85.38 | 648.9K | 61,202 | D | ↗ |
| 2026-03-25 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 24,727 | 80.26 | 1.98M | 61,202 | D | ↗ |
| 2026-03-23 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 52,975 | 77.21 | 4.09M | 76,721 | D | ↗ |
| 2026-03-20 | Esposito Pamela | Director | M-Exempt | A | Common Stock | 2,500 | 49.10 | 122.8K | 2,500 | D | ↗ |
| 2026-03-11 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 11,111 | 83.72 | 930.2K | 68,052 | D | ↗ |
| 2026-03-04 | Jacobs Bruce N. | Officer | S-Sale | D | Common Stock | 492 | 84.00 | 41.3K | 236,991 | D | ↗ |
| 2026-03-04 | Gollob Jared | Officer | S-Sale | D | Common Stock | 1,437 | 85.78 | 123.3K | 117,581 | D | ↗ |
| 2026-03-04 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 394 | 84.00 | 33.1K | 77,335 | D | ↗ |
| 2026-03-02 | Mainolfi Nello | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 215,000 | 90.10 | 19.37M | 215,000 | D | ↗ |
| 2026-03-02 | Jacobs Bruce N. | Officer | A-Award | A | Stock Option (Right to Buy) | 35,300 | 90.10 | 3.18M | 35,300 | D | ↗ |
| 2026-03-02 | Goodman Noah | Officer | A-Award | A | Common Stock | 9,225 | 0.00 | — | 59,306 | D | ↗ |
| 2026-03-02 | Gollob Jared | Officer | A-Award | A | Stock Option (Right to Buy) | 35,300 | 90.10 | 3.18M | 35,300 | D | ↗ |
| 2026-03-02 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 1,107 | 89.66 | 99.3K | 77,729 | D | ↗ |
| 2026-03-02 | Booth Bruce | Director | S-Sale | D | Common Stock | 71,814 | 90.13 | 6.47M | 3,902,667 | I | ↗ |
| 2026-03-02 | Adams Brian | Officer | A-Award | A | Common Stock | 4,125 | 0.00 | — | 56,625 | D | ↗ |
| 2026-02-25 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 30,000 | 2.08 | 62.4K | 245,559 | D | ↗ |
| 2026-02-20 | Esposito Pamela | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 49.10 | 122.8K | 2,500 | D | ↗ |
| 2026-01-20 | Esposito Pamela | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 49.10 | 122.8K | 5,000 | D | ↗ |
| 2026-01-05 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 3,118 | 32.07 | 100.0K | 666,195 | D | ↗ |
| 2025-12-31 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 2.08 | 62.4K | 693,077 | D | ↗ |
| 2025-12-17 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,595 | 38.53 | 100.0K | 272,505 | D | ↗ |
| 2025-12-17 | Esposito Pamela | Director | M-Exempt | A | Common Stock | 12,563 | 49.10 | 616.8K | 12,563 | D | ↗ |
| 2025-12-12 | Booth Bruce | Director | S-Sale | D | Common Stock | 108 | 91.04 | 9.8K | 685,393 | I | ↗ |
| 2025-12-11 | Booth Bruce | Director | S-Sale | D | Common Stock | 976 | 91.23 | 89.0K | 685,501 | I | ↗ |
| 2025-12-11 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,838,621 | 86.00 | 158.12M | 7,955,916 | I | ↗ |
| 2025-12-10 | Booth Bruce | Director | S-Sale | D | Common Stock | 3,391 | 89.25 | 302.6K | 713,876 | I | ↗ |
| 2025-12-08 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 2.08 | 208.0K | 305,559 | D | ↗ |
| 2025-12-08 | Gollob Jared | Officer | M-Exempt | D | Stock Option (Right to Buy) | 49,307 | 5.33 | 262.8K | 34,083 | D | ↗ |
| 2025-12-08 | Albers Jeffrey W. | Director | S-Sale | D | Common Stock | 2,252 | 90.30 | 203.4K | 0 | D | ↗ |
| 2025-10-29 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 2.08 | 62.4K | 690,482 | D | ↗ |
| 2025-10-15 | Gollob Jared | Officer | S-Sale | D | Common Stock | 8,963 | 61.49 | 551.2K | 131,341 | D | ↗ |
| 2025-10-13 | Gollob Jared | Officer | M-Exempt | A | Common Stock | 673 | 2.08 | 1.4K | 121,473 | D | ↗ |
| 2025-10-13 | Albers Jeffrey W. | Director | M-Exempt | A | Common Stock | 5,000 | 10.34 | 51.7K | 5,000 | D | ↗ |
| 2025-09-17 | Jacobs Bruce N. | Officer | M-Exempt | A | Common Stock | 79,220 | 2.08 | 164.8K | 306,629 | D | ↗ |
| 2025-09-16 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 30,000 | 2.08 | 62.4K | 435,559 | D | ↗ |
| 2025-09-03 | Adams Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 43.30 | 4.55M | 105,000 | D | ↗ |
| 2025-06-30 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 142,604 | 44.00 | 6.27M | 2,798,795 | D | ↗ |
| 2025-06-30 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Prefunded Warrants | 600,309 | 0.00 | 60.03 | 10,225,962 | I | ↗ |
| 2025-06-25 | Sandor Victor | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | Ridloff Elena | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | Esposito Pamela | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-25 | BVF PARTNERS L P/IL | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | I | ↗ |
| 2025-06-25 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 16,000 | 46.47 | 743.5K | 16,000 | I | ↗ |
| 2025-06-25 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 46.47 | 743.5K | 16,000 | D | ↗ |
| 2025-06-11 | Ridloff Elena | Director | M-Exempt | A | Common Stock | 4,500 | 20.29 | 91.3K | 4,500 | D | ↗ |
| 2025-06-03 | Ridloff Elena | Director | S-Sale | D | Common Stock | 4,800 | 47.00 | 225.6K | 0 | D | ↗ |
| 2025-06-03 | Mainolfi Nello | Director / Officer | S-Sale | D | Common Stock | 30,000 | 49.00 | 1.47M | 660,482 | D | ↗ |
| 2025-06-03 | Esposito Pamela | Director | S-Sale | D | Common Stock | 5,000 | 49.04 | 245.2K | 0 | D | ↗ |
| 2025-06-03 | Albers Jeffrey W. | Director | S-Sale | D | Common Stock | 6,349 | 49.00 | 311.1K | 0 | D | ↗ |
| 2025-05-23 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 2,575 | 29.30 | 75.4K | 66,420 | D | ↗ |
| 2025-04-08 | Goodman Noah | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,081 | D | ↗ |
| 2025-03-31 | Jacobs Bruce N. | Officer | M-Exempt | A | Common Stock | 25,000 | 2.08 | 52.0K | 226,886 | D | ↗ |
| 2025-03-03 | Mainolfi Nello | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 365,000 | 30.17 | 11.01M | 365,000 | D | ↗ |
| 2025-03-03 | Jacobs Bruce N. | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 208,921 | D | ↗ |
| 2025-03-03 | Gollob Jared | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 30.17 | 1.81M | 60,000 | D | ↗ |
| 2025-03-03 | Chiniara Ellen | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 82,326 | D | ↗ |
| 2025-03-03 | Chadwick Jeremy G | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 30.17 | 1.51M | 50,000 | D | ↗ |
| 2025-01-10 | Mainolfi Nello | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 10,000 | 2.08 | 20.8K | 495,559 | D | ↗ |
| 2025-01-10 | Jacobs Bruce N. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.08 | 20.8K | 94,899 | D | ↗ |
| 2025-01-06 | Chiniara Ellen | Officer | S-Sale | D | Common Stock | 3,129 | 41.75 | 130.6K | 54,826 | D | ↗ |
| 2024-12-02 | Esposito Pamela | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 29.55 | 73.9K | 29,127 | D | ↗ |
| 2024-09-17 | Esposito Pamela | Director | M-Exempt | A | Common Stock | 8,500 | 29.55 | 251.2K | 8,500 | — | ↗ |
| 2024-08-26 | Albers Jeffrey W. | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.34 | 51.7K | 11,349 | — | ↗ |
| 2024-08-21 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Prefunded Warrants | 2,246,587 | 0.00 | 224.66 | 9,625,653 | — | ↗ |
| 2024-08-20 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Pre-Funded Warrants to Purchase Common Stock | 156,742 | 0.00 | 15.67 | 156,742 | — | ↗ |
| 2024-08-20 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 1 | 46.41 | 46.41 | 5,516,986 | — | ↗ |
| 2024-07-16 | Gollob Jared | Officer | S-Sale | D | Common Stock | 13,281 | 45.59 | 605.5K | 105,604 | — | ↗ |
| 2024-07-15 | Gollob Jared | Officer | M-Exempt | A | Common Stock | 16,455 | 2.08 | 34.2K | 112,195 | — | ↗ |
| 2024-07-09 | Booth Bruce | Director | S-Sale | D | Common Stock | 38,606 | 38.48 | 1.49M | 743,484 | — | ↗ |
| 2024-07-01 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 18,773 | 5.33 | 100.1K | 649,959 | — | ↗ |
| 2024-06-27 | Jacobs Bruce N. | Officer | M-Exempt | A | Common Stock | 25,000 | 2.08 | 52.0K | 168,554 | — | ↗ |
| 2024-06-18 | Sandor Victor | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Ridloff Elena | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Morgan Leigh | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,413 | 2.08 | 30.0K | 505,559 | — | ↗ |
| 2024-06-18 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Esposito Pamela | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | BVF PARTNERS L P/IL | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-18 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 31.20 | 499.2K | 16,000 | — | ↗ |
| 2024-06-13 | Booth Bruce | Director | S-Sale | D | Common Stock | 8,430 | 34.98 | 294.9K | 4,548,400 | — | ↗ |
| 2024-06-12 | Booth Bruce | Director | S-Sale | D | Common Stock | 11,838 | 35.35 | 418.5K | 4,558,827 | — | ↗ |
| 2024-06-07 | Horobin Joanna | Director | S-Sale | D | Common Stock | 2,187 | 32.65 | 71.4K | 6,313 | — | ↗ |
| 2024-05-23 | Chadwick Jeremy G | Officer | S-Sale | D | Common Stock | 2,575 | 34.99 | 90.1K | 44,183 | — | ↗ |
| 2024-03-28 | BAKER BROS. ADVISORS LP | Director | — | I | Prefunded Warrants | 7,379,066 | 0.00 | 737.91 | 0 | — | ↗ |
| 2024-03-15 | Booth Bruce | Director | S-Sale | D | Common Stock | 49,591 | 40.62 | 2.01M | 4,572,258 | — | ↗ |
| 2024-03-14 | Booth Bruce | Director | S-Sale | D | Common Stock | 7,292 | 39.73 | 289.7K | 821,538 | — | ↗ |
| 2024-03-13 | Booth Bruce | Director | S-Sale | D | Common Stock | 108,404 | 42.19 | 4.57M | 4,682,761 | — | ↗ |
| 2024-03-13 | Atlas Venture Fund X, L.P. | 10% Owner | S-Sale | D | Common Stock | 108,404 | 42.19 | 4.57M | 4,682,761 | — | ↗ |
| 2024-03-12 | Booth Bruce | Director | S-Sale | D | Common Stock | 26,452 | 41.94 | 1.11M | 854,814 | — | ↗ |
| 2024-03-12 | Atlas Venture Fund X, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,819 | 42.52 | 77.3K | 852,995 | — | ↗ |
| 2024-03-11 | Booth Bruce | Director | S-Sale | D | Common Stock | 37,180 | 42.77 | 1.59M | 4,930,934 | — | ↗ |
| 2024-03-11 | Atlas Venture Fund X, L.P. | 10% Owner | S-Sale | D | Common Stock | 37,180 | 42.77 | 1.59M | 4,930,934 | — | ↗ |
| 2024-03-04 | Jacobs Bruce N. | Officer | S-Sale | D | Common Stock | 255 | 43.26 | 11.0K | 142,351 | — | ↗ |
| 2024-03-04 | Gollob Jared | Officer | S-Sale | D | Common Stock | 2,022 | 41.41 | 83.7K | 97,062 | — | ↗ |
| 2024-03-01 | Mainolfi Nello | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 530,000 | 43.50 | 23.06M | 530,000 | — | ↗ |
| 2024-03-01 | Jacobs Bruce N. | Officer | A-Award | A | Stock Option (Right to Buy) | 187,500 | 43.50 | 8.16M | 187,500 | — | ↗ |
| 2024-03-01 | Gollob Jared | Officer | A-Award | A | Common Stock | 24,375 | 0.00 | — | 99,084 | — | ↗ |
| 2024-03-01 | Chiniara Ellen | Officer | A-Award | A | Common Stock | 21,755 | 0.00 | — | 55,960 | — | ↗ |
| 2024-03-01 | Chadwick Jeremy G | Officer | A-Award | A | Stock Option (Right to Buy) | 80,548 | 43.50 | 3.50M | 80,548 | — | ↗ |
| 2024-02-27 | Gollob Jared | Officer | M-Exempt | A | Common Stock | 400 | 2.08 | 832.00 | 75,109 | — | ↗ |
| 2024-02-21 | Albers Jeffrey W. | Director | S-Sale | D | Common Stock | 4,385 | 39.05 | 171.2K | 0 | — | ↗ |
| 2024-02-20 | Albers Jeffrey W. | Director | M-Exempt | A | Common Stock | 615 | 10.34 | 6.4K | 615 | — | ↗ |
| 2024-02-09 | Gollob Jared | Officer | M-Exempt | A | Common Stock | 46,137 | 2.08 | 96.0K | 120,846 | — | ↗ |
| 2024-01-23 | Albers Jeffrey W. | Director | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 10.34 | 103.4K | 21,349 | — | ↗ |
| 2024-01-05 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Pre-Funded Warrants to Purchase Common Stock | 550,425 | 0.00 | 55.04 | 550,425 | — | ↗ |
| 2024-01-04 | Chiniara Ellen | Officer | S-Sale | D | Common Stock | 3,295 | 22.58 | 74.4K | 34,205 | — | ↗ |
| 2024-01-02 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,000 | 2.08 | 18.7K | 519,972 | — | ↗ |
| 2023-11-03 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 17,632 | 2.08 | 36.7K | 606,570 | — | ↗ |
| 2023-11-03 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 83,708 | 14.07 | 1.18M | 2,104,075 | — | ↗ |
| 2023-11-02 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 57,618 | 11.64 | 670.9K | 2,552,306 | — | ↗ |
| 2023-08-08 | Mainolfi Nello | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 2.08 | 25.0K | 2,368 | — | ↗ |
| 2023-06-15 | Sandor Victor | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Ridloff Elena | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Morgan Leigh | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Horobin Joanna | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Esposito Pamela | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | BVF PARTNERS L P/IL | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-15 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 27.67 | 332.0K | 12,000 | — | ↗ |
| 2023-06-02 | Jacobs Bruce N. | Officer | M-Exempt | A | Common Stock | 10,000 | 2.08 | 20.8K | 115,035 | — | ↗ |
| 2023-05-22 | Chadwick Jeremy G | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 29.64 | 5.93M | 200,000 | — | ↗ |
| 2023-03-02 | Jacobs Bruce N. | Officer | S-Sale | D | Common Stock | 1,056 | 30.88 | 32.6K | 104,882 | — | ↗ |
| 2023-03-02 | Gollob Jared | Officer | S-Sale | D | Common Stock | 1,001 | 30.88 | 30.9K | 75,006 | — | ↗ |
| 2023-03-02 | Caughey Elaine | Officer | S-Sale | D | Common Stock | 164 | 31.40 | 5.1K | 18,986 | — | ↗ |
| 2023-03-01 | Mainolfi Nello | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 32.07 | 14.43M | 450,000 | — | ↗ |
| 2023-03-01 | Jacobs Bruce N. | Officer | A-Award | A | Stock Option (Right to Buy) | 142,500 | 32.07 | 4.57M | 142,500 | — | ↗ |
| 2023-03-01 | Gollob Jared | Officer | A-Award | A | Stock Option (Right to Buy) | 112,500 | 32.07 | 3.61M | 112,500 | — | ↗ |
| 2023-03-01 | Caughey Elaine | Officer | A-Award | A | Common Stock | 10,557 | 0.00 | — | 19,700 | — | ↗ |
| 2023-01-12 | Booth Bruce | Director | S-Sale | D | Common Stock | 21,592 | 30.29 | 654.0K | 890,148 | — | ↗ |
| 2023-01-12 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 2,985 | 31.24 | 93.3K | 2,494,688 | — | ↗ |
| 2023-01-12 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 21,592 | 30.29 | 654.0K | 890,148 | — | ↗ |
| 2023-01-11 | Booth Bruce | Director | S-Sale | D | Common Stock | 6,071 | 29.96 | 181.9K | 911,740 | — | ↗ |
| 2023-01-11 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 11,149 | 29.89 | 333.2K | 1,872,439 | — | ↗ |
| 2023-01-11 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 21,683 | 29.96 | 649.6K | 5,045,242 | — | ↗ |
| 2023-01-03 | Chiniara Ellen | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 0.00 | — | 225,000 | — | ↗ |
| 2022-12-15 | Booth Bruce | Director | S-Sale | D | Common Stock | 2,561 | 30.00 | 76.8K | 5,066,925 | — | ↗ |
| 2022-12-15 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 2,561 | 30.00 | 76.8K | 5,066,925 | — | ↗ |
| 2022-12-14 | Booth Bruce | Director | S-Sale | D | Common Stock | 13,997 | 33.34 | 466.7K | 5,082,821 | — | ↗ |
| 2022-12-14 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 3,919 | 33.34 | 130.7K | 922,261 | — | ↗ |
| 2022-12-08 | Mainolfi Nello | Officer | M-Exempt | A | Common Stock | 10,000 | 2.08 | 20.8K | 573,700 | — | ↗ |
| 2022-11-03 | Sandor Victor | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-03 | Booth Bruce | Director | S-Sale | D | Common Stock | 21,085 | 30.00 | 632.6K | 1,001,417 | — | ↗ |
| 2022-11-03 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 75,312 | 30.00 | 2.26M | 5,365,563 | — | ↗ |
| 2022-11-02 | Booth Bruce | Director | S-Sale | D | Common Stock | 96,581 | 30.02 | 2.90M | 5,440,875 | — | ↗ |
| 2022-11-02 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 96,581 | 30.02 | 2.90M | 5,440,875 | — | ↗ |
| 2022-11-01 | Booth Bruce | Director | S-Sale | D | Common Stock | 15,804 | 30.57 | 483.1K | 1,050,584 | — | ↗ |
| 2022-11-01 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 1,044 | 31.08 | 32.4K | 1,049,540 | — | ↗ |
| 2022-10-31 | Booth Bruce | Director | S-Sale | D | Common Stock | 26,383 | 30.23 | 797.6K | 1,066,388 | — | ↗ |
| 2022-10-31 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 26,383 | 30.23 | 797.6K | 1,066,388 | — | ↗ |
| 2022-10-28 | Booth Bruce | Director | S-Sale | D | Common Stock | 19,915 | 30.00 | 597.5K | 1,092,771 | — | ↗ |
| 2022-10-28 | Atlas Venture Fund X, L.P. | Director | S-Sale | D | Common Stock | 71,135 | 30.00 | 2.13M | 5,691,877 | — | ↗ |
| 2022-10-21 | Jacobs Bruce N. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 139,899 | — | ↗ |
| 2022-10-17 | Mainolfi Nello | Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,676 | 0.00 | — | 546,604 | — | ↗ |
| 2022-10-17 | Jacobs Bruce N. | Officer | M-Exempt | A | Common Stock | 10,000 | 2.08 | 20.8K | 71,279 | — | ↗ |
| 2022-08-22 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock, $0.0001 par value | 27,117 | 26.00 | 705.0K | 257,754 | — | ↗ |
| 2022-07-06 | Morgan Leigh | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-06-29 | Ridloff Elena | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 20.29 | 182.6K | 9,000 | — | ↗ |
| 2022-06-15 | Ridloff Elena | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 14.18 | 170.2K | 12,000 | — | ↗ |
| 2022-06-15 | Nicholson Donald William | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 14.18 | 170.2K | 12,000 | — | ↗ |
| 2022-06-15 | LAMPERT MARK N | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-06-15 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-06-15 | Horobin Joanna | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-06-15 | Esposito Pamela | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-06-15 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-06-15 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-05-26 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock, $0.0001 par value | 3,223 | 14.78 | 47.6K | 230,637 | — | ↗ |
| 2022-05-20 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock, $0.0001 par value | 5,883 | 14.00 | 82.4K | 2,036,860 | — | ↗ |
| 2022-05-05 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock, $0.0001 par value | 70,439 | 19.60 | 1.38M | 1,466,364 | — | ↗ |
| 2022-05-04 | Gollob Jared | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,792 | 2.08 | 20.4K | 109,020 | — | ↗ |
| 2022-05-03 | Mainolfi Nello | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 2.08 | 41.6K | 502,199 | — | ↗ |
| 2022-05-03 | Jacobs Bruce N. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 2.08 | 41.6K | 159,899 | — | ↗ |
| 2022-03-01 | Mainolfi Nello | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,100 | 38.53 | 10.60M | 275,100 | — | ↗ |
| 2022-03-01 | Jacobs Bruce N. | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 38.53 | 3.08M | 80,000 | — | ↗ |
| 2022-03-01 | Gollob Jared | Officer | A-Award | D | Stock Option (Right to Buy) | 75,800 | 38.53 | 2.92M | 75,800 | — | ↗ |
| 2022-03-01 | Caughey Elaine | Officer | A-Award | A | Stock Option (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-01-31 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 14,323 | 40.70 | 582.9K | 1,395,925 | — | ↗ |
| 2022-01-27 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 58,042 | 38.33 | 2.22M | 1,880,187 | — | ↗ |
| 2022-01-24 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0001 par value | 158,041 | 37.76 | 5.97M | 1,822,145 | — | ↗ |
| 2022-01-18 | MARAGANORE JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 39.61 | 950.6K | 24,000 | — | ↗ |
| 2022-01-17 | MARAGANORE JOHN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-15.0K
Shares Outstanding
81.64M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 693.0K | — | — | 7.32M | 519.8K | 14.0K | 8.55M | 85.64% | ↗ |
| 2 | 2025 | Brian Adams, J.D. Chief Legal Officer | 145.2K | — | 2.27M | 3.56M | 90.6K | 6.3K | 6.07M | 96.01% | ↗ |
| 3 | 2025 | Noah Goodman, MBA Chief Business Officer | 294.0K | — | 1.05M | 1.63M | 181.7K | 12.8K | 3.17M | 84.60% | ↗ |
| 4 | 2025 | Jared Gollob, M.D. Chief Medical Officer | 507.1K | — | 905.1K | 1.20M | 285.2K | 14.0K | 2.91M | 72.33% | ↗ |
| 5 | 2025 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 500.0K | — | 905.1K | 1.20M | 281.3K | 14.0K | 2.90M | 72.61% | ↗ |
| 6 | 2024 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 670.0K | — | — | 14.21M | 542.7K | 13.8K | 15.43M | 92.05% | ↗ |
| 7 | 2024 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 481.0K | — | 1.36M | 5.03M | 259.7K | 13.8K | 7.14M | 89.43% | ↗ |
| 8 | 2024 | Jared Gollob, M.D. Chief Medical Officer | 490.0K | — | 1.06M | 3.92M | 264.6K | 13.8K | 5.75M | 86.64% | ↗ |
| 9 | 2024 | Ellen Chiniara, J.D. Chief Legal Officer | 461.0K | — | 946.3K | 3.50M | 221.3K | 13.8K | 5.14M | 86.46% | ↗ |
| 10 | 2024 | Jeremy Chadwick, Ph.D. Chief Operating Officer | 490.0K | — | 584.0K | 2.16M | 215.6K | 13.8K | 3.46M | 79.22% | ↗ |
| 11 | 2023 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 640.0K | — | — | 8.59M | 422.4K | 13.2K | 9.67M | 88.88% | ↗ |
| 12 | 2023 | Jeremy Chadwick, Ph.D. Chief Operating Officer | 295.4K | — | 988.0K | 3.59M | 117.8K | 11.1K | 5.00M | 91.52% | ↗ |
| 13 | 2023 | Ellen Chiniara, J.D. Chief Legal Officer | 433.3K | — | 931.5K | 3.39M | 190.4K | 13.2K | 4.96M | 87.17% | ↗ |
| 14 | 2023 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 470.0K | — | 761.7K | 2.72M | 188.0K | 13.2K | 4.16M | 83.85% | ↗ |
| 15 | 2023 | Jared Gollob, M.D. Chief Medical Officer | 480.0K | — | 601.3K | 2.15M | 230.4K | 13.2K | 3.47M | 79.17% | ↗ |
| 16 | 2022 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 600.0K | — | — | 5.95M | 363.0K | 12.2K | 6.93M | 85.92% | ↗ |
| 17 | 2022 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 441.7K | — | 512.4K | 1.73M | 194.4K | 12.2K | 2.89M | 77.59% | ↗ |
| 18 | 2022 | Jared Gollob, M.D. Chief Medical Officer | 460.0K | — | 485.5K | 1.64M | 165.6K | 12.2K | 2.77M | 76.93% | ↗ |
| 19 | 2022 | Elaine Caughey, MBA Chief Business Officer | 403.3K | — | 269.7K | 886.4K | 112.9K | 12.2K | 1.68M | 68.63% | ↗ |
| 20 | 2021 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 570.6K | — | — | 10.62M | 369.5K | 11.6K | 11.57M | 91.78% | ↗ |
| 21 | 2021 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 415.5K | — | — | 3.97M | 207.0K | 11.6K | 4.60M | 86.21% | ↗ |
| 22 | 2021 | Jared Gollob, M.D. Chief Medical Officer | 432.6K | — | — | 2.83M | 224.1K | 11.6K | 3.50M | 80.91% | ↗ |
| 23 | 2021 | Elaine Caughey, MBA Chief Business Officer | 199.2K | — | — | 2.82M | 101.7K | 8.0K | 3.13M | 90.13% | ↗ |
| 24 | 2021 | Richard Chesworth, Ph.D. Former Chief Scientific Officer | 314.0K | — | — | 1.70M | — | 74.4K | 2.09M | 81.39% | ↗ |
| 25 | 2020 | Richard Chesworth, Ph.D. Former Chief Scientific Officer | 144.9K | — | — | 4.33M | 60.0K | — | 4.53M | 95.48% | ↗ |
| 26 | 2020 | Richard Chesworth, Ph.D. Chief Scientific Officer | 144.9K | — | — | 4.33M | 60.0K | — | 4.53M | 95.48% | ↗ |
| 27 | 2020 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 453.6K | — | — | 2.85M | 379.0K | — | 3.68M | 77.36% | ↗ |
| 28 | 2020 | Jared Gollob, M.D. Chief Medical Officer | 383.2K | — | — | 875.5K | 194.0K | — | 1.45M | 60.27% | ↗ |
| 29 | 2020 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 369.0K | — | — | 696.9K | 197.0K | — | 1.26M | 55.18% | ↗ |
| 30 | 2019 | Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer | 362.5K | — | — | 1.30M | 142.1K | — | 1.81M | 72.11% | ↗ |
| 31 | 2019 | Jared Gollob, M.D. Chief Medical Officer | 344.9K | — | — | 299.9K | 113.4K | — | 688.2K | 43.58% | ↗ |
| 32 | 2019 | Bruce Jacobs, CFA, MBA Chief Financial Officer | 172.6K | — | — | 447.5K | 59.1K | — | 679.3K | 65.88% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | 1M | — |
| Jared A. Gollob | Chief Medical Officer | 768.4K | — |
| Bruce N. Jacobs | Chief Financial Officer | 754.5K | male |
| Jeremy G. Chadwick | Chief Operating Officer | 719.4K | — |
| Brian R. Adams | Chief Legal Officer & Corporate Secretary | 696.1K | male |
| Bruce L. Booth DPHIL | Co-Founder & Independent Chairman | 70.0K | — |
| Juliet Williams | Head of Research | — | — |
| Justine E. Koenigsberg | Vice President of Investor Relations | — | female |
| Karen Weisbach | Head of People & Culture | — | female |
| Neil Graham MBBS | Chief Development Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KYMR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
